Zhong Xue-Mei, Liu Xu-Rui
Department of Endocrinology, School of Clinical Medicine, Chongqing Medical and Pharmaceutical College, Chongqing 401331, P.R. China.
Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Oncol Lett. 2025 Apr 9;29(6):284. doi: 10.3892/ol.2025.15030. eCollection 2025 Jun.
Colorectal cancer (CRC) is the third most common cancer worldwide and there is a controversy regarding the influence of laxative use on the incidence of CRC. Therefore, the present study aimed to investigate the effects of laxative use and different subtypes of laxatives on the incidence of CRC. To this aim, a comprehensive search of three databases (PubMed, Embase and the Cochrane Library) was conducted on April 12, 2022, using key words that included 'laxative' and 'CRC', which initially retrieved 305 records. Ultimately, 12 studies involving 415,313 patients met all eligibility criteria and were included in a meta-analysis. Subsequently, patients were categorized into the laxative use and non-laxative use groups. Stata 16.0 software was used for all data analyses. The results indicated that laxative use was not significantly associated with CRC risk [odds ratio (OR), 0.95; 95% confidence interval (CI), 0.75-1.20; P=0.65; I=94.63%]. In the subgroup analyses, the effects of different laxative types were further examined. Notably, all types of laxatives except for fiber laxatives showed no significant influence on CRC risk (P>0.1). By contrast, fiber laxatives were associated with a reduced risk of CRC (OR, 0.74; 95% CI, 0.59-0.93; P=0.01; I=32.15%), suggesting a potential protective effect of this medication. In conclusion, the findings of the present study suggest that the use of laxatives does not increase the risk of CRC. Moreover, the use of fiber laxatives may have a protective effect by reducing CRC incidence.
结直肠癌(CRC)是全球第三大常见癌症,关于使用泻药对CRC发病率的影响存在争议。因此,本研究旨在调查使用泻药及不同类型泻药对CRC发病率的影响。为此,于2022年4月12日对三个数据库(PubMed、Embase和Cochrane图书馆)进行了全面检索,使用了包括“泻药”和“CRC”在内的关键词,最初检索到305条记录。最终,12项涉及415313名患者的研究符合所有纳入标准,并被纳入荟萃分析。随后,将患者分为使用泻药组和未使用泻药组。所有数据分析均使用Stata 16.0软件。结果表明,使用泻药与CRC风险无显著相关性[比值比(OR),0.95;95%置信区间(CI),0.75 - 1.20;P = 0.65;I = 94.63%]。在亚组分析中,进一步检查了不同类型泻药的影响。值得注意的是,除纤维类泻药外,所有类型的泻药对CRC风险均无显著影响(P>0.1)。相比之下,纤维类泻药与CRC风险降低相关(OR,0.74;95% CI,0.59 - 0.93;P = 0.01;I = 32.15%),表明该药物具有潜在的保护作用。总之,本研究结果表明,使用泻药不会增加CRC风险。此外,使用纤维类泻药可能通过降低CRC发病率而具有保护作用。